title: [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
abstract: BACKGROUND
  The identification of RAS status (KRAS and NRAS) has changed the management of metastatic colorectal cancer (mCRC). The impact of the RAS mutation on cytotoxic chemotherapy efficacy has not yet been determined. Nevertheless, several retrospective studies suggest a greater efficacy of oxaliplatin in mCRC with KRAS mutation.
  
  
  METHODS
  We analyzed retrospectively the progression free survival (PFS) and overall survival (OS) in 216 patients with mCRC receiving first line treatment between 2008 and 2010 according to KRAS status and chemotherapy regimen used (oxaliplatin- or irinotecan-based, in association with fluoropyrimidine and bevacizumab).
  
  
  RESULTS
  In KRAS mutated tumors, median OS was 23.4 months with oxaliplatin-based regimen, and 23.6 months with irinotecan-based regimen, with no significant difference (HR 1.30; 95 % CI 0.81-2.09; P=0.27). In KRAS wild-type tumors, median OS was 30.3 months with oxaliplatin-based regimen, and 25.4 months with irinotecan-based regimen, with no significant difference (HR 0.81; 95 % CI 0.52-1.24; P=0.33). Similarly, KRAS mutational status had no significant effect on efficacy of oxaliplatin or irinotecan regarding PFS.
  
  
  CONCLUSIONS
  In this retrospective study, KRAS mutational status does not influence the efficacy of first line cytotoxic chemotherapy in association with bevacizumab.
authors.affiliation: Institut de cancérologie de l'Ouest (ICO) René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France. Electronic address: mathilde.cabart@ico.unicancer.fr.
authors.forename: Mathilde
authors.initials: M
authors.lastname: Cabart
authors.affiliation: Institut de cancérologie de l'Ouest (ICO) René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
authors.forename: Jean-Sébastien
authors.initials: JS
authors.lastname: Frénel
authors.affiliation: Institut de cancérologie de l'Ouest (ICO) René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
authors.forename: Loïc
authors.initials: L
authors.lastname: Campion
authors.affiliation: Centre Catherine-de-Sienne, 2, rue Eric-Tabarly, 44200 Nantes, France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Ramée
authors.affiliation: Centre Jean-Bernard, 9, rue Beauverger, 72000 Le Mans, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Dupuis
authors.affiliation: Institut de cancérologie de l'Ouest (ICO) René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Senellart
authors.affiliation: Institut de cancérologie de l'Ouest (ICO) René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Hiret
authors.affiliation: Institut de cancérologie de l'Ouest (ICO) René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Douillard
authors.affiliation: Institut de cancérologie de l'Ouest (ICO) René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
authors.forename: Jaafar
authors.initials: J
authors.lastname: Bennouna
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005602:France; D011905:Genes, ras; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077150:Oxaliplatin; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: Bevacizumab; Bévacizumab; Cancer colorectal; Colorectal cancer; Irinotecan; Irinotécan; KRAS; Metastasis; Métastases; Oxaliplatine